PURINONE COMPOUNDS AND THEIR USE IN TREATING CANCER

The specification generally relates to compounds of Formula (I):and pharmaceutically acceptable salts thereof, where R1, A1, A2 and A3 have any of the meanings defined herein. The specification also relates to the use of such compounds and salts thereof to treat or prevent DNA-PK mediated disease, i...

Full description

Saved in:
Bibliographic Details
Main Authors GOLDBERG, Frederick Woolf, TING, Attilla Kuan Tsuei, FINLAY, Maurice Raymond Verschoyle, HOWARD, Martin Richard
Format Patent
LanguageEnglish
Published 09.05.2024
Subjects
Online AccessGet full text

Cover

Loading…
Abstract The specification generally relates to compounds of Formula (I):and pharmaceutically acceptable salts thereof, where R1, A1, A2 and A3 have any of the meanings defined herein. The specification also relates to the use of such compounds and salts thereof to treat or prevent DNA-PK mediated disease, including cancer. The specification further relates to pharmaceutical compositions comprising such compounds and salts; kits comprising such compounds and salts; methods of manufacture of such compounds and salts; intermediates useful in the manufacture of such compounds and salts; and to methods of treating DNA-PK mediated disease, including cancer, using such compounds and salts.
AbstractList The specification generally relates to compounds of Formula (I):and pharmaceutically acceptable salts thereof, where R1, A1, A2 and A3 have any of the meanings defined herein. The specification also relates to the use of such compounds and salts thereof to treat or prevent DNA-PK mediated disease, including cancer. The specification further relates to pharmaceutical compositions comprising such compounds and salts; kits comprising such compounds and salts; methods of manufacture of such compounds and salts; intermediates useful in the manufacture of such compounds and salts; and to methods of treating DNA-PK mediated disease, including cancer, using such compounds and salts.
Author HOWARD, Martin Richard
GOLDBERG, Frederick Woolf
TING, Attilla Kuan Tsuei
FINLAY, Maurice Raymond Verschoyle
Author_xml – fullname: GOLDBERG, Frederick Woolf
– fullname: TING, Attilla Kuan Tsuei
– fullname: FINLAY, Maurice Raymond Verschoyle
– fullname: HOWARD, Martin Richard
BookMark eNrjYmDJy89L5WQwDggN8vTz93NVcPb3DfAP9XMJVnD0c1EI8XD1DFIIDXZV8PRTCAlydQzx9HNXcHb0c3YN4mFgTUvMKU7lhdLcDMpuriHOHrqpBfnxqcUFicmpeakl8aHBRgZGJoamBsampo6GxsSpAgA6gCmn
ContentType Patent
DBID EVB
DatabaseName esp@cenet
DatabaseTitleList
Database_xml – sequence: 1
  dbid: EVB
  name: esp@cenet
  url: http://worldwide.espacenet.com/singleLineSearch?locale=en_EP
  sourceTypes: Open Access Repository
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
Chemistry
Sciences
ExternalDocumentID US2024150355A1
GroupedDBID EVB
ID FETCH-epo_espacenet_US2024150355A13
IEDL.DBID EVB
IngestDate Fri Jul 19 10:32:03 EDT 2024
IsOpenAccess true
IsPeerReviewed false
IsScholarly false
Language English
LinkModel DirectLink
MergedId FETCHMERGED-epo_espacenet_US2024150355A13
Notes Application Number: US202318540129
OpenAccessLink https://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20240509&DB=EPODOC&CC=US&NR=2024150355A1
ParticipantIDs epo_espacenet_US2024150355A1
PublicationCentury 2000
PublicationDate 20240509
PublicationDateYYYYMMDD 2024-05-09
PublicationDate_xml – month: 05
  year: 2024
  text: 20240509
  day: 09
PublicationDecade 2020
PublicationYear 2024
RelatedCompanies CANCER RESEARCH TECHNOLOGY LIMITED
ASTRAZENECA AB
RelatedCompanies_xml – name: CANCER RESEARCH TECHNOLOGY LIMITED
– name: ASTRAZENECA AB
Score 3.5286264
Snippet The specification generally relates to compounds of Formula (I):and pharmaceutically acceptable salts thereof, where R1, A1, A2 and A3 have any of the meanings...
SourceID epo
SourceType Open Access Repository
SubjectTerms CHEMISTRY
HETEROCYCLIC COMPOUNDS
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
Title PURINONE COMPOUNDS AND THEIR USE IN TREATING CANCER
URI https://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20240509&DB=EPODOC&locale=&CC=US&NR=2024150355A1
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3dS8MwED_GFPVNp-LHlIDStyKuXWcehmxp5iosLf2QvY2myWAg3XAV_32vYdM97S3JweUDLr-75D4AHnM3d6RS0lZU57brdZWdowVm91RH615Oi5750Z0Ib5y579PutAGf21gYkyf0xyRHRIkqUN4rc1-v_h-xfONbuX6SCxxavo7Svm9trGOEJwRAyx_2eRT6IbMY62eJJWJDQ90H0XWAttJBrUjXmfb5x7COS1ntgsroFA4j5FdWZ9DQZQuO2bb2WguOJpsvb2xupG99Dk6UxYEIBScsnERhJvyEDIRP0jEPYpIlnASCpDEfpIF4I6wuOxNfwMOIp2xs4-yzv83OsmR3qc4lNMtlqa-AuJ7XkZIq5Tl1krPiZU41lVrSYo5a0Pz5Gtr7ON3sJ9_CSd01rny0Dc3q61vfIdxW8t6c0i9oOH6j
link.rule.ids 230,309,786,891,25594,76906
linkProvider European Patent Office
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3dS8MwED_GFOebTsWPqQGlb0Vcu9Y8DNnSzlbXtPRD9jaaJgVBuuEq_vumYdM97S3k4PIBl99d7gvgPjdzg3HOdI5FrpvWgOu5tMB0m_eFsHNc2MqjG1DLy8zX2WDWgs9NLoyqE_qjiiNKiSqkvNfqvV7-f2I5KrZy9cA-5NTieZIOHW1tHUt4kgCoOeOhG4VOSDRChlmi0VjRpO4j0XUkbaU9u6nP2yhP7-MmL2W5DSqTI9iPJL-qPoaWqLrQIZvea104CNYubzlcS9_qBIwoi30aUheRMIjCjDoJGlEHpZ7rxyhLXORTlMbuKPXpCyJN25n4FO4mbko8Xa4-_zvsPEu2t2qcQbtaVOIckGlZfcYw55bRFDkrnkosMBMMF6XUgsrHC-jt4nS5m3wLHS8NpvOpT9-u4LAhqbA-3IN2_fUtriX01uxG3dgvfHWBkA
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Apatent&rft.title=PURINONE+COMPOUNDS+AND+THEIR+USE+IN+TREATING+CANCER&rft.inventor=GOLDBERG%2C+Frederick+Woolf&rft.inventor=TING%2C+Attilla+Kuan+Tsuei&rft.inventor=FINLAY%2C+Maurice+Raymond+Verschoyle&rft.inventor=HOWARD%2C+Martin+Richard&rft.date=2024-05-09&rft.externalDBID=A1&rft.externalDocID=US2024150355A1